Clovis Oncology Inc. (CLVS) had a good day on the market for Tuesday December 10 as shares jumped 12.98% to close at $12.10. About 17.88 million shares traded hands on 58,289 trades for the day, compared with an average daily volume of n/a shares out of a total float of 54.82 million. After opening the trading day at $11.00, shares of Clovis Oncology Inc. stayed within a range of $12.60 to $10.80.
With today’s gains, Clovis Oncology Inc. now has a market cap of $663.26 million. Shares of Clovis Oncology Inc. have been trading within a range of $32.05 and $2.94 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm target its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.
Clovis Oncology Inc. is based out of Boulder, CO and has some 468 employees. Its CEO is Patrick J. Mahaffy.
Clovis Oncology Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
